It’s good NEWS for the Investors of Sun Pharmaceutical Industries Investors as it gained 3.4% in the trade on Thursday as finally, it got the USFDA approval for its drug Ilumya –a drug to get recover from the Psoriasis.

Ilumya is widely used for the treatment of the plague psoriasis – a perpetual immune disease that affects your skin. The medicine Ilumya commonly called as the tildrakizumab-asmn falls in the list of specialty drugs which can treat the complex diseases like skin conditions autoimmune disorders and cancer.

Abhay Gandhi, Chief Executive Officer & President, USA, Sun Pharma said that “With the USFDA approval of ILUMYA & our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis.”